Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation
Cancer radio-immunotherapy, integrating external/internal radiation therapy with immuno-
oncology treatments, emerges in the current management of cancer. A growing number of …
oncology treatments, emerges in the current management of cancer. A growing number of …
Remotely controlled near-infrared-triggered photothermal treatment of brain tumours in freely behaving mice using gold nanostar s
Current clinical brain tumour therapy practices are based on tumour resection and post-
operative chemotherapy or X-ray radiation. Resection requires technically challenging open …
operative chemotherapy or X-ray radiation. Resection requires technically challenging open …
Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
S Liu, W Wang, S Hu, B Jia, B Tuo, H Sun… - Cell Death & …, 2023 - nature.com
Cancer immunotherapy has transformed traditional treatments, with immune checkpoint
blockade being particularly prominent. However, immunotherapy has minimal benefit for …
blockade being particularly prominent. However, immunotherapy has minimal benefit for …
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
L Hovhannisyan, C Riether, DM Aebersold, M Medová… - Molecular cancer, 2023 - Springer
CAR T cell-based therapies have revolutionized the treatment of hematological
malignancies such as leukemia and lymphoma within the last years. In contrast to the …
malignancies such as leukemia and lymphoma within the last years. In contrast to the …
Beyond the blood: expanding CAR T cell therapy to solid tumors
U Uslu, CH June - Nature Biotechnology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cell therapy stands as a transformative advancement in
immunotherapy, triumphing against hematological malignancies and, increasingly …
immunotherapy, triumphing against hematological malignancies and, increasingly …
[HTML][HTML] GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma
Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …
GD2 CAR T cells against human glioblastoma
Glioblastoma is the most malignant primary brain tumor and is still in need of effective
medical treatment. We isolated patient-derived glioblastoma cells showing high GD2 …
medical treatment. We isolated patient-derived glioblastoma cells showing high GD2 …
Radiation-induced tumor immune microenvironments and potential targets for combination therapy
S Guo, Y Yao, Y Tang, Z Xin, D Wu, C Ni… - … and Targeted Therapy, 2023 - nature.com
As one of the four major means of cancer treatment including surgery, radiotherapy (RT),
chemotherapy, immunotherapy, RT can be applied to various cancers as both a radical …
chemotherapy, immunotherapy, RT can be applied to various cancers as both a radical …
Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery
Background Immunotherapy with chimeric antigen receptor (CAR) T cells is actively being
explored for pediatric brain tumors in preclinical models and early phase clinical studies. At …
explored for pediatric brain tumors in preclinical models and early phase clinical studies. At …